GEO Accession viewer

NCBI > GEO > Accession Display

Not logged in | Login

GEO help: Mouse over screen elements for information.

Series GSE50233

Query DataSets for GSE50233

Status

Public on Aug 26, 2015

Title

Post-vaccination serum anti-glycan total Ig antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:200)

Platform organisms

Quercus alba; Gossypium hirsutum; Rhodotorula; Pandalus borealis; Gallus gallus; Homo sapiens; Bos taurus; Ovis aries; Mus musculus; Megathura crenulata; Bothrops moojeni; Frangula alnus; Senegalia senegal; Pachymenia carnosa; Dermestes lardarius

Sample organism

Experiment type

Protein profiling by protein array

Summary

Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. This study uses a high-throughput glycan microarray to assess correlations between a subject's overall survival after receiving PROSTVAC-VF and his anti-glycan humoral responses occuring in the first months after treatment with PROSTVAC-VF.
Results: Humoral responses to the terminal Forssman disaccharide (Fsdi) were found to have a statistically significant correlation with survival. Long-term survival was approximately doubled in subjects with four-fold or larger anti-Fsdi responses relative to subjects with little or no anti-Fsdi response. This survival correlation was specific to vaccine treatment, as no correlation was observed in control patients immunized with wild-type poxviruses lacking the key tumor antigen, prostate specific antigen (PSA). Moreover, anti-Fsdi humoral responses were not correlated with general measures of disease severity, such as PSA levels, Gleason score, or Halabi predicted survival.
Conclusion: In addition to reporting a new biomarker for monitoring benefical responses to PROSTVAC-VF, this study highlights the potential of glycan microarray technology for personalized medicine.

Overall design

The overall study was a retrospective analysis of 141 subjects from phase II trials of PROSTVAC-VF, a poxvirus based cancer vaccine currently in phase III clinical trials for advanced prostate cancer. The subjects were divided into a training set (n=28) and a validation set (n=113). A glycan microarray was used to profile pre-vaccination and post-vaccination anti-glycan antibody populations in sera as potential biomarkers for PROSTVAC-VF. For both the training set and validation set, the anti-glycan profiles were measured using four variations of serum dilution and isotype specific secondary antibody (IgM at 1:50, IgG at 1:50, total Ig at 1:50, and total Ig at 1:200). Total immunoglobin (IgM + IgG + IgA) levels for the training set measured at serum dilution of 1:200 are detailed here. The screen for response biomarkers identified anti-glycan humoral responses that consistently stratified subjects into groups with different Kaplan Meier survival estimates.
Raw data on SuperSeries GSE50410 record.

Contributor(s)

Campbell CT, Gulley JL, Oyelaran O, Hodge JW, Schlom J, Gildersleeve JC

Citation missing

Has this study been published? Please login to update or notify GEO.

Submission date

Aug 27, 2013

Last update date

Aug 26, 2015

Contact name

Christopher Campbell

Organization name

NCI

Street address

376 Boyles Street

City

Frederick

State/province

MD

ZIP/Postal code

21702

Country

USA

Platforms (1)

NCI Glycoarray-204

Samples (28)

More...

GSM1216215	Training patient #3 \| Vaccine Arm \| Day 85 \| Training Total Ig 1-200
GSM1216216	Training patient #24 \| Vaccine Arm \| Day 95 \| Training Total Ig 1-200
GSM1216217	Training patient #5 \| Vaccine Arm \| Day 84 \| Training Total Ig 1-200

GSM1216218	Training patient #26 \| Vaccine Arm \| Day 57 \| Training Total Ig 1-200
GSM1216219	Training patient #12 \| Vaccine Arm \| Day 80 \| Training Total Ig 1-200
GSM1216220	Training patient #29 \| Vaccine Arm \| Day 83 \| Training Total Ig 1-200
GSM1216221	Training patient #14 \| Vaccine Arm \| Day 82 \| Training Total Ig 1-200
GSM1216222	Training patient #27 \| Vaccine Arm \| Day 85 \| Training Total Ig 1-200
GSM1216223	Training patient #20 \| Vaccine Arm \| Day 81 \| Training Total Ig 1-200
GSM1216224	Training patient #30 \| Vaccine Arm \| Day 34 \| Training Total Ig 1-200
GSM1216225	Training patient #23 \| Vaccine Arm \| Day 83 \| Training Total Ig 1-200
GSM1216226	Training patient #28 \| Vaccine Arm \| Day 83 \| Training Total Ig 1-200
GSM1216227	Training patient #31 \| Vaccine Arm \| Day 82 \| Training Total Ig 1-200
GSM1216228	Training patient #2 \| Vaccine Arm \| Day 85 \| Training Total Ig 1-200
GSM1216229	Training patient #16 \| Vaccine Arm \| Day 26 \| Training Total Ig 1-200
GSM1216230	Training patient #21 \| Vaccine Arm \| Day 89 \| Training Total Ig 1-200
GSM1216231	Training patient #32 \| Vaccine Arm \| Day 85 \| Training Total Ig 1-200
GSM1216232	Training patient #1 \| Vaccine Arm \| Day 85 \| Training Total Ig 1-200
GSM1216233	Training patient #8 \| Vaccine Arm \| Day 86 \| Training Total Ig 1-200
GSM1216234	Training patient #9 \| Vaccine Arm \| Day 85 \| Training Total Ig 1-200
GSM1216235	Training patient #15 \| Vaccine Arm \| Day 82 \| Training Total Ig 1-200
GSM1216236	Training patient #22 \| Vaccine Arm \| Day 88 \| Training Total Ig 1-200
GSM1216237	Training patient #25 \| Vaccine Arm \| Day 90 \| Training Total Ig 1-200
GSM1216238	Training patient #4 \| Vaccine Arm \| Day 81 \| Training Total Ig 1-200
GSM1216239	Training patient #7 \| Vaccine Arm \| Day 87 \| Training Total Ig 1-200
GSM1216240	Training patient #10 \| Vaccine Arm \| Day 79 \| Training Total Ig 1-200
GSM1216241	Training patient #13 \| Vaccine Arm \| Day 82 \| Training Total Ig 1-200
GSM1216242	Training patient #19 \| Vaccine Arm \| Day 83 \| Training Total Ig 1-200

This SubSeries is part of SuperSeries:

Anti-glycan humoral responses after vaccination with PROSTVAC-VF

Relations

BioProject

Download family	Format
SOFT formatted family file(s)	SOFT
MINiML formatted family file(s)	MINiML
Series Matrix File(s)	TXT

Supplementary data files not provided

Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |